This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Witt: I'm so glad ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Red blood cell distribution width (RDW) may be a good biomarker for chronic obstructive pulmonary disease (COPD) severity, study finds. There is a positive association between increased red blood cell ...

Please provide your email address to receive an email when new articles are posted on . Exacerbation risk factors in this population included GERD, chronic bronchitis, high symptom burden and ...

Patients with chronic obstructive pulmonary disease (COPD) that is in a state of disease stability (DS) have fewer exacerbations and lower mortality, according to study findings published in Chest.

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

A pulmonary and critical care medicine physician discusses how bronchiectasis compares with other chronic respiratory disorders, highlighting the differing signs and symptoms. Stay ahead of policy, ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has highlighted recent advances in understanding and managing COPD, particularly in relation to its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with moderate or severe COPD receiving 300 mg of ...

Paris and Tarrytown, N.Y. November 27, 2023. The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly ...